genistein + paclitaxel + carboplatin

Genistein + paclitaxel + carboplatin is a combination regimen comprised of three distinct agents: - **Genistein** is an isoflavone found in soy products, classified as a phytoestrogen and often investigated as a dietary supplement or experimental therapy for its anti-cancer effects. It exerts cytotoxic and pro-apoptotic effects in cancer cells by modulating several signaling pathways, including inhibition of Akt and ERK phosphorylation and activation of p38 and JNK pathways[1]. - **Paclitaxel** is a small molecule chemotherapeutic agent that stabilizes microtubules and inhibits their depolymerization, leading to cell cycle arrest and apoptosis in rapidly dividing cells. - **Carboplatin** is a platinum-based chemotherapeutic that induces DNA cross-linking and subsequent apoptosis, particularly effective in cells with impaired DNA repair mechanisms. Paclitaxel and carboplatin are an established combination, forming the backbone of first-line therapy for several cancers such as epithelial ovarian cancer, triple-negative breast cancer, and non-small cell lung cancer[2][3][4][5][6]. The addition of genistein is primarily pre-clinical or experimental, considered investigational for use in humans alongside standard chemotherapy. Genistein may synergize with platinum agents and taxanes, enhancing cytotoxicity and apoptosis in various cancer cell lines, and modulating oncogenic pathways[1]. There is limited published clinical data on this exact three-drug combination, but preclinical evidence suggests potentiation of apoptosis and attenuation of pro-survival signaling.

Other names

genistein + paclitaxel + carboplatin